A Phase 4 interventional study of Levetiracetam 250 mg and Levetiracetam 500 mg in Healthy Subjects and Renal Impairments, sponsored by UCB Pharma. Completed at 2 sites in Japan. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-10.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a human pharmacology, single-dose study to investigate the pharmacokinetics of orally administered Levetiracetam (LEV) in Japanese subjects with normal renal function and in Japanese subjects with various degrees of impaired renal function.
The primary objective of this study is to evaluate the plasma and urine PK of Levetiracetam (ucb L059) and its metabolite (ucb L057) after a single dose of LEV 250 mg or LEV 500 mg in Japanese subjects with normal renal function and in Japanese subjects with various degrees of renal impairment.
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who have normal renal function (CLcr \>80 mL/min/1.73 m\^2). Subjects will be orally administered Levetiracetam (LEV) 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be taken through to Day 4 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments. * Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours postdose * Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72 hours postdose
Drug: Levetiracetam 500 mg
Patients who have mild renal impairment (50\<CLcr \<80 mL/min/1.73 m\^2). Subjects will be orally administered (Levetiracetam) LEV 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 5 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments. * Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 hours postdose * Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96 hours postdose
Drug: Levetiracetam 500 mg
Patients who have moderate renal impairment (30\<CLcr \< 50 mL/min/1.73 m\^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 6 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments. * Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose * Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120 hours postdose
Drug: Levetiracetam 250 mg
Patients who have severe renal impairment (CLcr \<30 mL/min/1.73 m\^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 7 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments. * Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours postdose * Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120, 120 - 144 hours postdose
Drug: Levetiracetam 250 mg
Group E will receive Levetiracetam (LEV) 500 mg on Day 1, 44 hours (h) before the first hemodialysis. As a supplementary dose LEV 250 mg will be administered 1 h after the end of the first hemodialysis on Day 3. The 4-h Hemodialysis are scheduled as follows: 1. Dialysis: 44 h to 48 h after the first dose (Day 3) 2. Dialysis: 92 h to 96 h after the first dose (Day 5) 3. Dialysis: 140 h after the first dose (Day 7) Safety assessments and blood samplings will be conducted until Day 7. Safety follow-up assessments will be performed on Day 10. Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 30, 44\*, 44.25\*, 44.5\*, 45\*, 46\*, 47\*, 48\*, 49, 49.5, 50, 51, 53, 55, 57, 61, 73, 92, 96, 120, 140 hours post first dosing. 49 h-sample should be taken before the additional dose. The 44 h, 92 h, and 140 h sample should be taken before the start of the hemodialysis. \*Inflow blood, outflow blood, and dialysate fluid will be collected.
Drug: Levetiracetam 250 mg · Drug: Levetiracetam 500 mg
Tablet containing Levetiracetam 250 mg
Also known as: E-Keppra
Tablet containing Levetiracetam 500 mg
Also known as: E-Keppra
Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Groups A to D
Cmax refers to the maximum observed concentration of L059 (Levetiracetam). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to the Last Quantifiable Concentration for Groups A to D
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Maximum Observed Plasma Concentration (Cmax) of Ucb L057 for Groups A to D
Cmax refers to the maximum observed concentration of ucb L057. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to the Last Quantifiable Concentration for Groups A to D
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Group E During First Period
Cmax refers to the maximum observed concentration of ucb L059 (Levetiracetam).
Time frame: From Baseline to 44 hours post first dose
Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to 44 Hours for Group E
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.
Time frame: From Baseline to 44 hours post first dose
Maximum Observed Plasma Concentration (Cmax) of Ucb L057 for Group E During First Period
Cmax refers to the maximum observed concentration of ucb L057.
Time frame: From Baseline to 44 hours post first dose
Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to 44 Hours for Group E
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.
Time frame: From Baseline to 44 hours post first dose
Total Amount Excreted in Urine (Ae) of Ucb L059 (LEV) for Groups A to D
Ae refers to the total amount of ucb L059 (Levetiracetam) excreted in urine. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Fraction of Dose Excreted in Urine (fe) of Ucb L059 (LEV) for Groups A to D
fe refers to the fraction of dose excreted in urine of L059 (Levetiracetam). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Renal Clearance (CLR) of Ucb L059 (LEV) for Groups A to D
Renal clearance describes the removal of drug from a volume of plasma in a given unit of time by the kidneys. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Apparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Groups A to D
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It indicates the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time period. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Nonrenal Clearance (CLNR) of Ucb L059 (LEV) for Groups A to D
The Non-Renal Clearance (CLNR) describes the removal of drug by organs other than the kidneys. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Total Amount Excreted in Urine (Ae) of Ucb L057 for Groups A to D
Ae refers to the total amount of ucb L057 excreted in urine. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Renal Clearance (CLR) of Ucb L057 for Groups A to D
Renal clearance describes the removal of drug from a volume of plasma in a given unit of time by the kidneys. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Apparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Group E During First Period
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It indicates the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time period. Geometric mean and Coefficient of Variation (CV) was not calculated since the extrapolated part of the AUC was greater than 20 %.
Time frame: From Baseline to 44 hours post first dose
Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (LEV) for Groups A to D
tmax refers to the time to reach maximum plasma concentration of ucb L059 (Levetiracetam). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Area Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Groups A to D
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Terminal Half-life (t1/2) of Ucb L059 (LEV) for Groups A to D
Terminal half-life refers to the time it takes for the concentrations to decrease by half. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Groups A to D
tmax refers to the time to reach maximum plasma concentration (tmax). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Area Under the Concentration-time Curve (AUC) of Ucb L057 From Baseline to Infinite for Groups A to D
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Terminal Half-life (t1/2) of Ucb L057 for Groups A to D
Terminal half-life refers to the time it takes for the concentrations to decrease by half. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
Time frame: From Baseline up to 144 hours post first dose
Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (Levetiracetam) for Group E During First Period
tmax refers to the time to reach the maximum plasma concentration of ucb L059 (Levetiracetam).
Time frame: From Baseline to 44 hours post first dose
Area Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Group E
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %.
Time frame: From Baseline to 140 hours post first dose
Terminal Half-life (t1/2) of Ucb L059 (LEV) for Group E During First Period
Terminal half-life refers to the time it takes for the concentrations to decrease by half. Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %.
Time frame: From Baseline to 44 hours post first dose
Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Group E During First Period
tmax refers to the time to reach maximum plasma concentration (tmax).
Time frame: From Baseline to 44 hours post first dose
Hemodialysis Clearance (CLD) of Ucb L059 (LEV) During First Dialysis for Group E
Calculated by the Arterio - Venous difference method and cumulative dialysate method.
Time frame: From 44 hours to 48 hours post first dose
Ultrafiltration Clearance (CLUF) of Ucb L059 (LEV) During First Dialysis for Group E
Calculated by the Arterio - Venous difference method and cumulative dialysate method.
Time frame: From 44 hours to 48 hours post first dose
Hemodialysis Clearance (CLHD) of Ucb L059 (LEV) During First Dialysis for Group E
Calculated according: CLHD=CLD+CLUF.
Time frame: From 44 hours to 48 hours post first dose
The Participant Flow refers to the Safety Set population which includes all patients that received at least one dose of study medication.
| Milestone | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment | Group E: End-stage Renal Disease |
|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Cmax refers to the maximum observed concentration of L059 (Levetiracetam). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| µg/mL | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Groups A to D | 21.9357 ± 31.2 | 15.5334 ± 25.3 | 10.7767 ± 24.3 | 9.1754 ± 30.4 |
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| h*µg/mL | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to the Last Quantifiable Concentration for Groups A to D | 165.9996 ± 16.5 | 247.6430 ± 16.9 | 169.3392 ± 16.5 | 212.1193 ± 19.1 |
Cmax refers to the maximum observed concentration of ucb L057. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| µg/mL | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Ucb L057 for Groups A to D | 0.3620 ± 9.4 | 0.7503 ± 25.8 | 0.5674 ± 26.0 | 1.0640 ± 29.3 |
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| h*µg/mL | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to the Last Quantifiable Concentration for Groups A to D | 5.8607 ± 9.7 | 22.5573 ± 45.9 | 18.6675 ± 53.4 | 57.7773 ± 57.3 |
Cmax refers to the maximum observed concentration of ucb L059 (Levetiracetam).
| µg/mL | Group E: End-stage Renal Disease |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Group E During First Period | 18.6810 ± 8.1 |
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.
| h*µg/mL | Group E: End-stage Renal Disease |
|---|---|
| Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to 44 Hours for Group E | 462.4883 ± 10.5 |
Cmax refers to the maximum observed concentration of ucb L057.
| µg/mL | Group E: End-stage Renal Disease |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Ucb L057 for Group E During First Period | 8.8435 ± 7.0 |
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.
| h*µg/mL | Group E: End-stage Renal Disease |
|---|---|
| Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to 44 Hours for Group E | 230.4393 ± 7.8 |
Ae refers to the total amount of ucb L059 (Levetiracetam) excreted in urine. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| mg | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Total Amount Excreted in Urine (Ae) of Ucb L059 (LEV) for Groups A to D | 304.7321 ± 30.3 | 247.6562 ± 12.5 | 98.7182 ± 11.9 | 74.3761 ± 34.4 |
fe refers to the fraction of dose excreted in urine of L059 (Levetiracetam). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| Percentage of Dose Administered | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Fraction of Dose Excreted in Urine (fe) of Ucb L059 (LEV) for Groups A to D | 60.9464 ± 30.3 | 49.5312 ± 12.5 | 39.4873 ± 11.9 | 29.7504 ± 34.4 |
Renal clearance describes the removal of drug from a volume of plasma in a given unit of time by the kidneys. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| L/h | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Renal Clearance (CLR) of Ucb L059 (LEV) for Groups A to D | 1.8622 ± 27.4 | 0.9820 ± 22.1 | 0.5671 ± 17.6 | 0.3417 ± 49.3 |
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It indicates the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time period. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| L/h | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Apparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Groups A to D | 2.9359 ± 14.8 | 1.9826 ± 16.0 | 1.4362 ± 15.3 | 1.1484 ± 19.1 |
The Non-Renal Clearance (CLNR) describes the removal of drug by organs other than the kidneys. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| L/h | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Nonrenal Clearance (CLNR) of Ucb L059 (LEV) for Groups A to D | 1.0712 ± 50.6 | 0.9873 ± 17.4 | 0.8636 ± 18.4 | 0.7848 ± 17.9 |
Ae refers to the total amount of ucb L057 excreted in urine. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| mg | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Total Amount Excreted in Urine (Ae) of Ucb L057 for Groups A to D | 83.5936 ± 16.9 | 169.3395 ± 19.0 | 93.1346 ± 14.0 | 100.7489 ± 17.8 |
Renal clearance describes the removal of drug from a volume of plasma in a given unit of time by the kidneys. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| L/h | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Renal Clearance (CLR) of Ucb L057 for Groups A to D | 14.6937 ± 18.3 | 6.8015 ± 32.6 | 4.6828 ± 45.6 | 1.6475 ± 42.0 |
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It indicates the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time period. Geometric mean and Coefficient of Variation (CV) was not calculated since the extrapolated part of the AUC was greater than 20 %.
| L/h | Group E: End-stage Renal Disease |
|---|---|
| Apparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Group E During First Period | 0.629 (0.500 to 0.801) |
tmax refers to the time to reach maximum plasma concentration of ucb L059 (Levetiracetam). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| hours | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (LEV) for Groups A to D | 0.500 (0.500 to 2.000) | 1.000 (0.500 to 2.000) | 0.500 (0.500 to 1.000) | 0.500 (0.500 to 1.000) |
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| h*µg/mL | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Area Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Groups A to D | 170.3045 ± 14.8 | 252.1923 ± 16.0 | 174.0764 ± 15.3 | 217.6854 ± 19.1 |
Terminal half-life refers to the time it takes for the concentrations to decrease by half. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| hours | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Terminal Half-life (t1/2) of Ucb L059 (LEV) for Groups A to D | 7.6164 ± 6.9 | 12.6214 ± 11.3 | 15.5033 ± 17.5 | 19.7320 ± 26.5 |
tmax refers to the time to reach maximum plasma concentration (tmax). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| hours | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Groups A to D | 5.000 (2.000 to 8.000) | 8.000 (6.000 to 12.000) | 12.000 (8.000 to 12.000) | 24.000 (12.000 to 24.000) |
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| h*µg/mL | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Area Under the Concentration-time Curve (AUC) of Ucb L057 From Baseline to Infinite for Groups A to D | 8.176 ± 0 | 32.401 (28.910 to 38.917) | 27.441 (16.472 to 41.184) | 63.126 (48.016 to 171.348) |
Terminal half-life refers to the time it takes for the concentrations to decrease by half. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours
| hours | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment |
|---|---|---|---|---|
| Terminal Half-life (t1/2) of Ucb L057 for Groups A to D | 12.351 (11.348 to 15.310) | 19.030 (17.331 to 19.903) | 20.303 (19.681 to 23.569) | 26.769 (17.249 to 33.348) |
tmax refers to the time to reach the maximum plasma concentration of ucb L059 (Levetiracetam).
| hours | Group E: End-stage Renal Disease |
|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (Levetiracetam) for Group E During First Period | 0.720 (0.430 to 0.980) |
AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %.
| h*µg/mL | Group E: End-stage Renal Disease |
|---|---|
| Area Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Group E | 794.588 ± 10.5 |
Terminal half-life refers to the time it takes for the concentrations to decrease by half. Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %.
| hours | Group E: End-stage Renal Disease |
|---|---|
| Terminal Half-life (t1/2) of Ucb L059 (LEV) for Group E During First Period | 34.669 (29.227 to 38.648) |
tmax refers to the time to reach maximum plasma concentration (tmax).
| hours | Group E: End-stage Renal Disease |
|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Group E During First Period | 44.020 (44.000 to 44.030) |
Calculated by the Arterio - Venous difference method and cumulative dialysate method.
| mL/min | Group E: End-stage Renal Disease |
|---|---|
| Hemodialysis Clearance (CLD) of Ucb L059 (LEV) During First Dialysis for Group E | 113.9665 ± 8.5 |
Calculated by the Arterio - Venous difference method and cumulative dialysate method.
| mL/min | Group E: End-stage Renal Disease |
|---|---|
| Ultrafiltration Clearance (CLUF) of Ucb L059 (LEV) During First Dialysis for Group E | 1.3271 ± 32.5 |
Calculated according: CLHD=CLD+CLUF.
| mL/min | Group E: End-stage Renal Disease |
|---|---|
| Hemodialysis Clearance (CLHD) of Ucb L059 (LEV) During First Dialysis for Group E | 115.3702 ± 8.1 |
Collected over Treatment-Emergent Adverse Events were reported from Day 1 up to Day 8 (+2 days) for Group A to D and from Day 1 up to Day 10 (+2 days) for Group E.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: Normal Renal Function | — | 0/6 (0%) | 0/6 (0%) |
| Group B: Mild Renal Impairment | — | 0/6 (0%) | 2/6 (33.3%) |
| Group C: Moderate Renal Impairment | — | 0/6 (0%) | 0/6 (0%) |
| Group D: Severe Renal Impairment | — | 0/6 (0%) | 1/6 (16.7%) |
| Group E: End-stage Renal Disease | — | 1/6 (16.7%) | 2/6 (33.3%) |
| Event | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment | Group E: End-stage Renal Disease |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| Shunt malfunctionInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| Event | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment | Group E: End-stage Renal Disease |
|---|---|---|---|---|---|
| GingivitisGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 |
| ToothacheGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 |
| PyrexiaGeneral disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 |
| NasopharyngitisInfections and infestations | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 |
| Postoperative wound complicationInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| White blood cell count increasedInvestigations | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| DizzinessNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
The Baseline Analysis Population refers to the Pharmacokinetic Per Protocol Set (PK-PPS) which consists of all subjects included in the Safety Set (SS), who also had a sufficient number of bioanalytical assessments (plasma or urine) to calculate reliable estimates for the PK parameters.
| Age, Continuous(years) | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment | Group E: End-stage Renal Disease | Total |
|---|---|---|---|---|---|---|
| Mean | 61.7 ± 2.6 | 67.5 ± 5.0 | 69.3 ± 6.1 | 55.8 ± 17.1 | 68.8 ± 7.9 | 64.6 ± 10.0 |
| Age, Customized(participants) | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment | Group E: End-stage Renal Disease | Total |
|---|---|---|---|---|---|---|
| 20 - <65 years | 5 | 3 | 1 | 4 | 2 | 15 |
| >=65 years | 1 | 3 | 5 | 2 | 4 | 15 |
| Sex: Female, Male(Participants) | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment | Group E: End-stage Renal Disease | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 0 | 0 | 0 | 0 | 1 |
| Male | 5 | 6 | 6 | 6 | 6 | 29 |
| Race/Ethnicity, Customized(participants) | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment | Group E: End-stage Renal Disease | Total |
|---|---|---|---|---|---|---|
| Asian | 6 | 6 | 6 | 6 | 6 | 30 |
| Race/Ethnicity, Customized(participants) | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment | Group E: End-stage Renal Disease | Total |
|---|---|---|---|---|---|---|
| Japanese | 6 | 6 | 6 | 6 | 6 | 30 |
| Weight(kilogram) | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment | Group E: End-stage Renal Disease | Total |
|---|---|---|---|---|---|---|
| Mean | 60.95 ± 10.97 | 74.28 ± 4.14 | 63.07 ± 12.49 | 58.70 ± 6.10 | 62.20 ± 5.41 | 63.84 ± 9.62 |
| Height(centimeters) | Group A: Normal Renal Function | Group B: Mild Renal Impairment | Group C: Moderate Renal Impairment | Group D: Severe Renal Impairment | Group E: End-stage Renal Disease | Total |
|---|---|---|---|---|---|---|
| Mean | 161.73 ± 9.05 | 165.65 ± 3.11 | 163.72 ± 5.64 | 164.50 ± 6.34 | 162.38 ± 3.41 | 163.60 ± 5.68 |
The record gives a start of Nov 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam